Drugs / DTaP vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05432141 | Jun → Sep 2022 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP vaccine | “All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines.” NCT05432141 ↗ |
| Known as | DTaP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05432141 ↗ |
| Modality | Vaccine | “All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines.” NCT05432141 ↗ |
| Route | Intramuscular | “Subjects recommended intramuscular injection.” NCT05432141 ↗ |